Press release
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis)Revenue of $4.50 billion for fiscal year 2023, down 2% from
About this update from Illumina, Inc.
[{"type":"text","content":"Revenue of $1.12 billion for Q4 2023, up 4% from Q4 2022 (up 4% on a constant currency basis)Revenue of $4.50 billion for fiscal year 2023, down 2% from fiscal year 2022 (flat on a constant currency basis)Shipped 79 NovaSeq X instruments in Q4 2023 and 352 instruments for fiscal year 2023GAAP diluted loss per share of $(1.11) for Q4 2023, compared to GAAP diluted loss per share of $(0.89) for Q4 2022Non-GAAP diluted earnings per share of $0.14 for both Q4 2023 and Q4 2022GAAP diluted loss per share of $(7.34) for fiscal year 2023, which included goodwill and intangible impairments of $821 million related to the GRAIL segment, compared to GAAP diluted loss per share of $(28.00) for fiscal year 2022, which included goodwill impairment of $3.91 billion related to the GRAIL segmentNon-GAAP diluted earnings per share of $0.86 for fiscal year 2023, compared to non-GAAP diluted earnings per share of $2.12 for fiscal year 2022For fiscal year 2024, expect Core Illumina revenue that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin of approximately 20%On December 17, 2023, Illumina announced it will divest GRAIL. The GRAIL divestiture will be executed through a third-party sale or capital markets transaction, consistent with the European Commission's divestiture order, with the goal of finalizing the divestiture terms by the end of the second quarter of this year. The timing of Illumina's progress with the divestment is not affected by external factors, including, but not limited to, the outcome of the European Court of Justice appeal and the potential preliminary NHS rollout of Galleri in the UKSAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) (\"Illumina\" or the \"company\") today announced its financial results for the fourth quarter and fiscal year 2023, which include the consolidated financial results for GRAIL.\n\n\"I'm pleased that in the fourth quarter, my first full quarter with the company, Illumina delivered results ahead of our expectations, driven by NovaSeq X instrument and consumables sales,\" said Jacob Thaysen, Chief Executive Officer. \"While our customers generally remain constrained in their purchasing, we are well-positioned for growth as market conditions improve. Illumina is focused on three key priorities to accelerate value creation: driving our top line; foc...